Public Profile

Gilead Sciences

Gilead Sciences, Inc., a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative healthcare since its founding in 1987. With a strong presence in regions such as Europe and Asia, Gilead focuses on the research, development, and commercialisation of antiviral drugs, particularly for HIV, hepatitis B, hepatitis C, and influenza. The company is renowned for its groundbreaking therapies, including Biktarvy and Harvoni, which have transformed the treatment landscape for chronic viral infections. Gilead's commitment to advancing medicine is underscored by its significant achievements, including multiple FDA approvals and a robust pipeline of investigational therapies. As a key player in the biopharmaceutical industry, Gilead Sciences continues to shape the future of healthcare through its dedication to scientific innovation and patient care.

DitchCarbon Score

How does Gilead Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

58

Industry Average

Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

24

Industry Benchmark

Gilead Sciences's score of 58 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.

99%

Let us know if this data was useful to you

Gilead Sciences's reported carbon emissions

In 2023, Gilead Sciences reported total carbon emissions of approximately 1,179,798,000 kg CO2e, comprising 56,096,000 kg CO2e from Scope 1, 22,339,000 kg CO2e from Scope 2, and 1,121,798,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 46% by 2030, using 2019 as the baseline year. Additionally, Gilead has committed to a 15% reduction in absolute Scope 3 emissions over the same timeframe. Gilead's emissions data shows a consistent effort to monitor and manage its carbon footprint across all scopes. The company is also working towards achieving carbon net-zero operational GHG emissions by 2030 for both Scope 1 and Scope 2 emissions. These initiatives align with industry standards for climate action and demonstrate Gilead's commitment to sustainability within the pharmaceutical sector.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20162017201820192020202120222023
Scope 1
44,754,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
29,127,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
32,003,000
00,000,000
00,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Gilead Sciences's primary industry is Research and development services (73), which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Gilead Sciences is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Gilead Sciences is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Sanofi

FR
Pharmaceutical Preparation Manufacturing
Updated about 16 hours ago

Eli Lilly and Company

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Genmab

DK
Medical, precision and optical instruments, watches and clocks (33)
Updated 1 day ago

Alexion Pharmaceuticals, Inc.

US
Health and social work services (85)
Updated 3 months ago
DitchCarbon Score

Glaxosmithkline

GB
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Ucb

BE
Medical, precision and optical instruments, watches and clocks (33)
Updated 1 day ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers